Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Finasteride effectively blocks rat enzymes, but with varying methods and strength.

This study found that isozyme profiles in polyoma virus-induced tumors were consistent and distinctive for each tumor type, except for salivary and mammary tumors which shared a profile.

This review discusses the biochemical properties and clinical significance of 5 alpha-reductase isozymes and reports no new clinical results.

This review describes the roles of 5α-reductase isozymes in prostate development and pathology and reports no new clinical results.

This study found that sebaceous glands predominantly exhibit oxidative activity of the type 2 17β-hydroxysteroid dehydrogenase isozyme, which is not inhibited by 13-cis retinoic acid.

This study suggests that the COX-2 enzyme plays a role in hair follicle biology, as transgenic overexpression in mice induced hair follicle cycling disturbances and alopecia, which was mitigated by COX-2 inhibition.

This study found that women with female pattern hair loss had increased 5α-reductase isozymes and decreased aromatase mRNA levels, potentially affecting their response to treatment.

This study found that the pH dependency of rat steroid 5α-reductase type II isozyme significantly affects its kinetic properties, including Vmax and Km, suggesting past discrepancies in literature may arise from these pH variances during assays.

In this study, 4-(4-(phenylaminocarbonyl)benzoyl) benzoic acid exhibited the strongest inhibitory activity against the human type 2 steroid 5α-reductase isozyme among the compounds tested.

This study found that 5alpha-reductase type 1 localizes specifically to sebaceous glands in both normal and acne follicles, suggesting its role in sebum regulation.

In this study, dutasteride more effectively reduced prostate cancer cell viability than finasteride in vitro, but did not significantly alter the angiogenic response.

This study identified CYP3A4 as a key isozyme involved in the oxidative metabolism of finasteride in human liver microsomes.

This study found that novel compounds moderately inhibited 5α-reductase type 1 activity compared to finasteride, offering valuable data on structure-activity relationships.

In this study, researchers found that young men with androgenic alopecia exhibited significantly higher mRNA levels of 5α-reductase isozymes and changes in prostate cancer-related genes, which could explain varying responses to treatment and guide future therapies.

This study concludes that rhesus macaques are a suitable model for testing the pharmacological properties of finasteride and other 5aR inhibitors, due to their biochemical similarity to humans.

This review summarizes recent advancements in steroidal 5α-reductase inhibitors for benign prostatic hyperplasia and reports no new clinical results.

This study found that cyclosporin A stimulates growth in cultured murine hair epithelial cells and reduces protein kinase C expression, suggesting that these actions may contribute to its hair-growing effects.

This review discusses the role of Cytochrome P-450 in dermatology and reports no new clinical results.

This study reported that newly synthesized nonsteroidal compounds were effective at inhibiting prostatic 5 alpha reductase isozyme 2, especially the compound with an N, N-diisopropylcarbamoyl substituent, suggesting potential for treating benign prostatic hyperplasia.

This article reviews the biochemical properties of 5 alpha-reductase isoforms and highlights the limited dermatological use of inhibitors like finasteride, especially for type 1 isozyme-targeting agents, while suggesting further clinical exploration.

Hair loss in androgenetic alopecia is caused by genetic factors and androgen excess, and can be treated with combined therapies.

This study identified LY191704 as a specific noncompetitive inhibitor of human 5 alpha-reductase type 1, which may be useful in treating endocrine disorders related to DHT overproduction.

This study suggests that 5α-reduced glucocorticoids may have anti-inflammatory potential and could serve as biomarkers for liver inflammation in metabolic disease, with implications for drug development.

This study found that 4-MA is a potent inhibitor of testosterone 5α-reductase in human tissues, promising potential for treating androgen-dependent skin conditions like male pattern baldness.

This study reported that newly synthesized phenanthridin-3-one derivatives effectively inhibit human steroid 5-α-reductase.

In this study, novel substituted benzoyl benzoic acids and phenylacetic acids were potent and selective inhibitors of human steroid 5alpha-reductase type 2, with one compound showing promising bioavailability in rats for potential clinical evaluation.

Saw palmetto extract can block the enzyme that converts testosterone in pig prostate cells.

This review discusses various targets for treating prostate cancer and benign prostatic hyperplasia and reports on recent studies of new compounds and 5α-reductase inhibitors, but provides no new experimental results.

This review discusses the pathophysiology of androgen-stimulated skin disorders and key clinical trials of 5α-reductase inhibitors for their treatment, but it does not report new clinical results.

This study found that 4-(4-Phenoxybenzoyl)benzoic acid derivatives may act as antioxidants by scavenging certain reactive oxygen species but exhibit prooxidant behavior under specific conditions.